Equities Analysts Set Expectations for ELAN Q2 Earnings

Elanco Animal Health Incorporated (NYSE:ELAN) – William Blair reduced their Q2 2025 EPS estimates for shares of Elanco Animal Health in a research report issued to clients and investors on Tuesday, February 25th. William Blair analyst B. Vazquez now anticipates that the company will post earnings per share of $0.22 for the quarter, down from their previous estimate of $0.27. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health’s Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.14 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.29 EPS, Q2 2026 earnings at $0.28 EPS, Q3 2026 earnings at $0.16 EPS, Q4 2026 earnings at $0.18 EPS and FY2026 earnings at $0.91 EPS.

ELAN has been the topic of several other research reports. UBS Group reduced their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Barclays reduced their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday. Stifel Nicolaus cut their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Finally, Morgan Stanley cut their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $15.57.

Elanco Animal Health Price Performance

ELAN stock opened at $11.15 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health has a 52 week low of $10.20 and a 52 week high of $18.80. The firm’s fifty day moving average is $11.74 and its 200 day moving average is $13.06. The firm has a market cap of $5.51 billion, a P/E ratio of 27.88, a P/E/G ratio of 2.50 and a beta of 1.42.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business posted $0.08 EPS. Elanco Animal Health’s revenue for the quarter was down 1.4% on a year-over-year basis.

Institutional Investors Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. DDD Partners LLC purchased a new position in Elanco Animal Health in the fourth quarter worth about $5,974,000. Geode Capital Management LLC raised its holdings in Elanco Animal Health by 0.8% in the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock worth $115,623,000 after buying an additional 65,303 shares during the last quarter. Atom Investors LP raised its holdings in Elanco Animal Health by 310.3% in the third quarter. Atom Investors LP now owns 345,855 shares of the company’s stock worth $5,081,000 after buying an additional 261,559 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in Elanco Animal Health by 24.0% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock worth $13,135,000 after buying an additional 209,734 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Elanco Animal Health by 19.2% in the third quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock worth $58,875,000 after acquiring an additional 646,522 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.